Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Statistiska Konsultgruppen, Gothenburg, Sweden.
ESC Heart Fail. 2021 Aug;8(4):3237-3247. doi: 10.1002/ehf2.13451. Epub 2021 May 31.
To study clinical phenotype, prognosis for all-cause and cardiovascular (CV) mortality and predictive factors in patients with incident heart failure (HF) after aortic valvular intervention (AVI) for aortic stenosis (AS).
In this retrospective, observational study we included patients from the Swedish Heart Failure Registry (SwedeHF) recorded 2003-2016, with AS diagnosis and AVI before HF diagnosis. The AS diagnosis was established according to International Classification of Diseases 10th revision (ICD-10) codes, thus without information concerning clinical or echocardiographical data on the aortic valve disease. The patients were divided into two subgroups: left ventricular ejection fraction (LVEF) ≥ 50% (AS-HFpEF) and <50% (AS-HFrEF). We individually matched three controls with HF from the SwedeHF without AS (control group) for each patient. Baseline characteristics, co-morbidities, survival status and outcomes were obtained by linking the SwedeHF with two other Swedish registries. We used Kaplan-Meier curves to present time to all-cause mortality, cumulative incidence function for time to CV mortality and Cox proportional hazards model to evaluate the relative difference between AS-HFrEF and AS-HFpEF and AS-HF and controls. The crude all-cause mortality was 49.0%, CV mortality 27.9% in AS-HF patients, respectively 44.7% and 26.6% in matched controls. The adjusted risk for all-cause mortality and CV mortality was similar in HF, regardless of LVEF vs. controls. No significant difference in factors predicting higher all-cause mortality was observed in AS-HFrEF vs. AS-HFpEF, except for diabetes (only in AS-HFrEF), with statistically significant interaction predicting death between the two groups.
In this nationwide SwedeHF study, we characterized incident HF population after AVI. We found no significant differences in all-cause and CV mortality compared with general HF population. They had virtually the same predictors for mortality, regardless of LVEF.
研究主动脉瓣狭窄(AS)患者主动脉瓣干预(AVI)后发生心力衰竭(HF)的临床表型、全因和心血管(CV)死亡率的预后以及预测因素。
在这项回顾性观察性研究中,我们纳入了 2003 年至 2016 年期间瑞典心力衰竭登记处(SwedeHF)记录的患者,这些患者有 AS 诊断和 HF 诊断之前的 AVI。AS 诊断是根据国际疾病分类第 10 版(ICD-10)编码确定的,因此没有关于主动脉瓣疾病的临床或超声心动图数据的信息。患者被分为两个亚组:左心室射血分数(LVEF)≥50%(AS-HFpEF)和<50%(AS-HFrEF)。我们为每位患者分别匹配了来自 SwedeHF 中没有 AS 的 3 名 HF 对照组患者。通过将 SwedeHF 与另外两个瑞典登记处相链接,获得了基线特征、合并症、生存状况和结局。我们使用 Kaplan-Meier 曲线呈现全因死亡率的时间,使用累积发病率函数呈现 CV 死亡率的时间,并使用 Cox 比例风险模型评估 AS-HFrEF 与 AS-HFpEF 以及 AS-HF 与对照组之间的相对差异。AS-HF 患者的全因死亡率为 49.0%,CV 死亡率为 27.9%,而匹配对照组患者的死亡率分别为 44.7%和 26.6%。HF 患者的全因死亡率和 CV 死亡率的调整风险与对照组相比相似,而无论 LVEF 如何。在 AS-HFrEF 与 AS-HFpEF 之间,除了糖尿病(仅在 AS-HFrEF 中)外,预测全因死亡率较高的因素没有观察到显著差异,两组之间的统计学显著交互作用预测了死亡。
在这项全国性的 SwedeHF 研究中,我们描述了 AVI 后发生 HF 的患者人群。与一般 HF 人群相比,我们发现全因和 CV 死亡率没有显著差异。他们的死亡率预测因素几乎相同,无论 LVEF 如何。